Vantage logo

Inclisiran keeps on giving

Five months after Novartis paid $9.7bn for the RNAi project’s maker, Blackstone has put down a $1bn bet on a partial royalty interest.

Vantage logo

Circassia averts its cash crunch

Payment of an overdue $120m Astrazeneca milestone, plus two other obligations, has been met through a loan facility with undisclosed terms.

Vantage logo
Independent, data-driven daily news and analysis on pharma, biotech and medtech.